SCHEMBL31678000

SCHEMBL31678000

C=CC(=O)Nc1c(Cl)cccc1-c1c(CC)nc2n(CC(=O)Nc3ccc(F)cc3)c(C)c(C)n2c1=O

nearest known ligand 0.36

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 3/20 0.36
▸ MEN1 O00255 2/20 0.36
▸ KDM4E B2RXH2 3/20 0.36
▸ SMN1; SMN2 Q16637 3/20 0.36
▸ ALDH1A1 P00352 3/20 0.36
▸ MAPT P10636 4/20 0.35
▸ FGFR2 P21802 2/20 0.34
▸ TGM2 P21980 1/20 0.34
▸ APOBEC3A P31941 1/20 0.34
▸ APOBEC3G Q9HC16 1/20 0.34
▸ FGFR1 P11362 1/20 0.33
▸ FGFR4 P22455 1/20 0.33
▸ FGFR3 P22607 1/20 0.33
▸ KDR P35968 1/20 0.33
▸ TP53 P04637 1/20 0.33
▸ LMNA P02545 1/20 0.33
▸ HPGD P15428 1/20 0.33
▸ RAB9A P51151 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31677853 0.88 KDM4E (0.42) KMT2AMEN1KDM4ESMN1; SMN2ALDH1A1
SCHEMBL31677653 0.81 MAPK3 (0.40) KMT2AMEN1SMN1; SMN2MAPTLMNA
SCHEMBL31677828 0.81 MEN1 (0.39) KMT2AMEN1KDM4ESMN1; SMN2MAPT
SCHEMBL31677868 0.80 RORC (0.40) KMT2AMEN1KDM4EALDH1A1MAPT
SCHEMBL31677654 0.80 KMT2A (0.43) KMT2AMEN1KDM4ESMN1; SMN2ALDH1A1
SCHEMBL31677686 0.79 RORC (0.39) KMT2AMEN1KDM4ESMN1; SMN2ALDH1A1
SCHEMBL31653824 0.79 KDM4E (0.46) KMT2AMEN1KDM4ESMN1; SMN2ALDH1A1
SCHEMBL31653762 0.78 KDM4E (0.42) KMT2AMEN1KDM4ESMN1; SMN2ALDH1A1
SCHEMBL31678236 0.77 KDM4E (0.39) KMT2AMEN1KDM4EALDH1A1MAPT
SCHEMBL31678128 0.75 ACHE (0.45) KMT2AMEN1KDM4ESMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250270217-A1 IMIDAZ0[1,2-A]PYRIMIDINE-5(1 H)-ONES HAVING A COVALENT WARHEAD AT THE 3-POSITION AS WRN INHIBITORS INCYTE CORPORATION (US) 2025-08-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250270217-A1 IMIDAZ0[1,2-A]PYRIMIDINE-5(1 H)-ONES HAVING A COVALENT WARHEAD AT THE 3-POSITION AS WRN INHIBITORS WRN, RECQL, BLM KMT2A 1697/4885MEN1 1859/4885KDM4E 2390/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback